Loading company
Innate Pharma SA
IPHA · Nasdaq · ·
$1.61-5.3%Sep 29 close
- 1M
- -27.5%
- 6M
- +27.8%
- 1Y
- -16.6%
- 5Y
- -77.3%
IPHA · Nasdaq · ·
$1.61-5.3%Sep 29 close
From the company’s own 6-K filing.
“2026 continues to be an important year of execution for Innate, marked by our strategic partnership with Sobi and the strengthening of our financial position,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
The quote and the company description come from the 6-K Innate Pharma SA filed on September 17, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
A short summary of each call — what the quarter showed, what management expects and whether they delivered on what they said last time — with the full transcript underneath.
Source: Yahoo Finance, transcribed by Quartr. Speaker names and roles are as transcribed; analysts are sometimes unnamed.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Call summaries are part of Pro
A two-minute read of every Innate Pharma SA earnings call: the numbers that mattered, what management expects, whether they delivered on last quarter’s outlook, and what analysts asked that went unanswered.
See one first on , , or — open to everyone.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.